Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.

Published in: Thoracic cancer (2020)

This meta-analysis confirmed that anti-PD-1 and anti-PD-L1 inhibitors had a lower incidence of irAEs compared with anti-CTLA-4 inhibitors.

Keyphrases